Evenamide as add-on treatment for treatment-resistant schizophrenia (TRS) patients not benefiting from antipsychotics: design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled clinical trial

Ravi Anand

[P503] Evenamide as add-on treatment for treatment-resistant schizophrenia (TRS) patients not benefiting from antipsychotics: design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled clinical trial

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Rodolfo Giuliani², Richard Hartman³ (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

Keywords:Treatment resistant schizophrenia, Phase 3 study, glutamate modulation, add-on treatment, evenamide

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Presentation information

Schizophrenia 5 - Clinical (3)

[P503] Evenamide as add-on treatment for treatment-resistant schizophrenia (TRS) patients not benefiting from antipsychotics: design of a phase 3, potentially pivotal, international, randomized, double-blind, placebo-controlled clinical trial

Password